← Back to home

LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

Clinical trials for LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION explained in plain language.

Never miss a new study

Get alerted when new LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION trials appear

Sign up with your email to follow new studies for LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

New hope for Hard-to-Treat breast cancer: drug combo targets gene mutation

Disease control Recruiting now

This study tests whether a new drug combination (lasofoxifene plus abemaciclib) works better than a standard combination (fulvestrant plus abemaciclib) for people with advanced ER+/HER2- breast cancer that has a specific gene change (ESR1 mutation). About 500 adults whose cancer …

Matched conditions: LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

Phase: PHASE3 • Sponsor: LeonaBio • Aim: Disease control

Last updated Jun 27, 2026 14:01 UTC

LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

Get alerted when new LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION trials appear

New hope for Hard-to-Treat breast cancer: drug combo targets gene mutation